Skip to main content
. Author manuscript; available in PMC: 2009 Jun 2.
Published in final edited form as: Neurochem Int. 2008 Dec 9;54(3-4):172–179. doi: 10.1016/j.neuint.2008.08.013

Fig. 6.

Fig. 6

Suppressed ERK activation in the tub/tub mice and the SF-protective effect. (A) Representative Western blots; (B) measurements of p-ERKs (activated ERK). CBB was used as the control. The total ERKs are also presented, showing no or less change with the treatment. SF treatment: daily intraperitoneally injection with SF (50 mg/kg in PBS) or PBS alone for 20 days from P10. The cochleae were harvested at P60 and P90. The measurements are expressed as mean ± S.D. (n = 4 in each group). *p < 0.05; **p < 0.01.